Learn more about COVID-19 in Saskatchewan. Daily case numbers and information for businesses and workers.

The Re-Open Saskatchewan plan was released on April 23rd.

Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow text box that resembles the link below and can be found in the right hand rail of the page. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

The results of software-based translation do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos, and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

New ALS Treatment Added To Saskatchewan Drug Plan

Released on June 30, 2020

Effective July 1, 2020, Saskatchewan will provide coverage of RADICAVA® (edaravone) for eligible residents under the Saskatchewan Drug Plan.

Radicava is an intravenous infusion treatment for people with amyotrophic lateral sclerosis (ALS).  ALS is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.  Studies have shown that Radicava can slow the progression of ALS for people newly diagnosed with ALS or in the early stages of the disease.

“Radicava is the first new ALS treatment available in Canada in many years,” Health Minister Jim Reiter said.  “While this is not a cure for ALS, we are proud to offer coverage for this treatment that can help people in the early stages of ALS slow the rate of progression of their disease.”

“We are so pleased that the Government of Saskatchewan recognizes the importance of this new drug for the ALS community, and we thank them for supporting those who will now have access to this treatment option by including it on the provincial formulary,” ALS Society of Saskatchewan Executive Director Denis Simard said.

The ALS Society of Saskatchewan is a community-based organization that works to raise funds and promote awareness of ALS while also supporting clients and families impacted by ALS.  Treatment with Radicava costs approximately $123,000 per patient in the first year of treatment, and $120,000 annually afterward.

For more information about the Saskatchewan Drug Plan, visit https://www.saskatchewan.ca/residents/health/prescription-drug-plans-and-health-coverage/extended-benefits-and-drug-plan/saskatchewan-drug-plan


For more information, contact:

Colleen Book
Phone: 306-787-4083
Email: media@health.gov.sk.ca

We need your feedback to improve saskatchewan.ca. Help us improve